GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Beneish M-Score
中文

Athersys (Athersys) Beneish M-Score

: -22.29 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -22.29 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Athersys's Beneish M-Score or its related term are showing as below:

ATHXQ' s Beneish M-Score Range Over the Past 10 Years
Min: -22.29   Med: 0.82   Max: 67.51
Current: -22.29

During the past 13 years, the highest Beneish M-Score of Athersys was 67.51. The lowest was -22.29. And the median was 0.82.


Athersys Beneish M-Score Historical Data

The historical data trend for Athersys's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.76 -4.49 -6.02 10.19 -5.98

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.01 -5.98 -7.37 -7.99 -22.29

Competitive Comparison

For the Biotechnology subindustry, Athersys's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Athersys's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Athersys's Beneish M-Score falls into.



Athersys Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Athersys for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1+0.404 * 3.6532+0.892 * 0.0133+0.115 * 0.5878
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 49.6431+4.679 * -2.073775-0.327 * 3.9459
=-22.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0.049 + 0 + 0.031 = $0.08 Mil.
Gross Profit was 0 + 0.049 + 0 + 0.031 = $0.08 Mil.
Total Current Assets was $2.23 Mil.
Total Assets was $7.43 Mil.
Property, Plant and Equipment(Net PPE) was $4.26 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.01 Mil.
Selling, General, & Admin. Expense(SGA) was $10.85 Mil.
Total Current Liabilities was $38.62 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -3.771 + -12.924 + -7.811 + -13.001 = $-37.51 Mil.
Non Operating Income was 4.009 + 0.064 + -0.477 + 0.659 = $4.26 Mil.
Cash Flow from Operations was -3.847 + -4.585 + -5.966 + -11.96 = $-26.36 Mil.
Total Receivables was $0.66 Mil.
Revenue was 0.065 + 2.316 + 2.912 + 0.722 = $6.02 Mil.
Gross Profit was 0.065 + 2.316 + 2.912 + 0.722 = $6.02 Mil.
Total Current Assets was $20.75 Mil.
Total Assets was $35.54 Mil.
Property, Plant and Equipment(Net PPE) was $13.57 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.72 Mil.
Selling, General, & Admin. Expense(SGA) was $16.44 Mil.
Total Current Liabilities was $38.73 Mil.
Long-Term Debt & Capital Lease Obligation was $8.11 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.08) / (0.66 / 6.015)
=0 / 0.109726
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.015 / 6.015) / (0.08 / 0.08)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.23 + 4.262) / 7.428) / (1 - (20.748 + 13.569) / 35.543)
=0.12601 / 0.034493
=3.6532

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.08 / 6.015
=0.0133

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.722 / (1.722 + 13.569)) / (1.01 / (1.01 + 4.262))
=0.112615 / 0.191578
=0.5878

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.852 / 0.08) / (16.436 / 6.015)
=135.65 / 2.732502
=49.6431

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 38.624) / 7.428) / ((8.109 + 38.729) / 35.543)
=5.199785 / 1.317784
=3.9459

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-37.507 - 4.255 - -26.358) / 7.428
=-2.073775

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Athersys has a M-score of -22.29 suggests that the company is unlikely to be a manipulator.


Athersys Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Athersys's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115